High Tumor Burden Predicts Poor Response to Enzalutamide in Metastatic Castration-Resistant Prostate Cancer Patients.

Yu-Ting Hsieh, Bing-Juin Chiang, Chia-Chang Wu, Chun-Hou Liao, Chia-Da Lin, Chung-Hsin Chen

Abstract read

In one paragraph

Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

Prostate Cancer: Pathophysiology, Pathology and Therapy.Cancers · 2022
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yu-Ting HsiehDepartment of Urology, National Taiwan University Hospital, Taipei 10002, Taiwan.

Bing-Juin ChiangDivision of Urology, Department of Surgery, Cardinal Tien Hospital and School of Medicine, Fu-Jen Catholic University, New Taipei City 23148, Taiwan.

Chia-Chang WuDepartment of Urology, Shuang Ho Hospital, Taipei Medical University, New Taipei City 23561, Taiwan.

Chun-Hou LiaoDivision of Urology, Department of Surgery, Cardinal Tien Hospital and School of Medicine, Fu-Jen Catholic University, New Taipei City 23148, Taiwan.

Chia-Da LinDepartment of Urology, Shuang Ho Hospital, Taipei Medical University, New Taipei City 23561, Taiwan.

Chung-Hsin ChenDepartment of Urology, National Taiwan University Hospital, Taipei 10002, Taiwan.ORCID 0000-0002-4921-5315

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To assess the predictive value of tumor burden on the biochemical response, and radiological response in Taiwanese metastatic castration-resistant prostate cancer (mCRPC) patients receiving enzalutamide. The mCRPC patients treated with enzalutamide were recruited from three hospitals. High tumor burden (HTB) was classified as metastases at either appendicular bone or visceral organ. Good prostate-specific antigen (PSA) response was defined as PSA reduction of 80%. In this cohort, there were 104 (54.2%) HTB patients and 88 (45.8%) with low tumor burden (LTB). Compared to LTB patients, fewer HTB patients had good PSA response (odds ratio: 0.43, range: 0.22-0.87,

Indexed as

enzalutamideprognosisprostate-specific antigenprostatic neoplasmstumor burden

Identifiers

PMID34439119

DOI10.3390/cancers13163966

PMCPMC8392339

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.